Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safinamide in Chinese Parkinson's Disease Patients (XINDI)
NCT03881371Phase 3Completed
- Sponsor
- Zambon
- Start
- Aug 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of safinamide in Parkinson's disease (PD), sponsored by Zambon. Started Aug 2019; status: completed.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03881371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03881371.